The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer

Brain Imaging and Behavior

Volumn 7, Issue 4, 2013, Pages 511-523

  Pomykala, K L ^a   Ganz, P A ^a,b   Bower, J E ^a,c,d   Kwan, L ^a   Castellon, S A ^a,e   Mallam, S ^a   Cheng, I ^a   Ahn, R ^a   Breen, E C ^a,d   Irwin, M R ^a,c,d   Silverman, D H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Brain imaging; Breast cancer; Chemotherapy; Cognitive complaints; Positron emission tomography; Pro inflammatory cytokines

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; TAMOXIFEN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EARLY CANCER; FEMALE; FRONTAL CORTEX; HUMAN; INFLAMMATION; MEMORY DISORDER; PRIORITY JOURNAL; TEMPORAL CORTEX;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BRAIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MIDDLE AGED; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84901330385     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-013-9243-2     Document Type: Article

References (57)

1. ACS (2011). Cancer Facts & Figures 2011. GA, USA.
2. Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. [Research support, N.I.H., extramural review]. Nature Reviews. Cancer, 7(3), 192-201. doi:10.1038/nrc2073.
3. Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. Journal of Clinical Oncology, 20(2), 485-493.
4. Ahles, T. A., Saykin, A. J., McDonald, B. C., Li, Y., Furstenberg, C. T., Hanscom, B. S., et al. (2010). Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. [Clinical Trial Research Support, N.I.H., extramural]. Journal of Clinical Oncology, 28(29), 4434-4440. doi:10.1200/JCO.2009.27.0827.
5. Alexander, S., Minton, O., Andrews, P., & Stone, P. (2009). A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. [Research Support, Non-U.S. Gov't]. European Journal of Cancer, 45(3), 384-392. doi:10.1016/j.ejca.2008.09.010.
6. Argyriou, A., Assimakopoulous, K., Iconomou, G., Giannakopoulou, F., & Kalofonos, H. (2011). Either called "Chemobrain" or "Chemofog" the long-term chemotherapy-induced cognitive decline in cancer survivors is real. Journal of Pain and Symptom Management, 41(1), 126-139.
7. Barber, R. (2011). Inflammatory signaling in Alzheimer disease and depression. [Review]. Cleveland Clinic Journal of Medicine, 78(Suppl 1), S47-S49. doi:10.3949/ccjm.78.s1.08.
8. Biglia, N., Bounous, V. E., Malabaila, A., Palmisano, D., Torta, D. M., D'Alonzo, M., et al. (2012). Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. European Journal of Cancer Care (England), 21(4), 485-492. doi:10.1111/j.1365-2354.2011.01320.x.
9. Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002). Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64(4), 604-611.
10. Bower, J. E., Ganz, P. A., Aziz, N., Olmstead, R., Irwin, M. R., & Cole, S. W. (2007). Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Brain, Behavior, and Immunity, 21(3), 251-258. doi:10.1016/j.bbi.2006.08.001.
11. Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., et al. (2009). Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Clinical Cancer Research, 15(17), 5534-5540. doi:10.1158/1078-0432.CCR-08-2584.
12. Bower, J. E., Ganz, P. A., Irwin, M. R., Kwan, L., Breen, E. C., & Cole, S. W. (2011). Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? [Research Support, N.I.H., Extramural]. Journal of Clinical Oncology, 29(26), 3517-3522. doi:10.1200/JCO.2011.36.1154.
13. Bower, J. E., Ganz, P. A., Irwin, M. R., Castellon, S., Arevalo, J., & Cole, S.W. (2013). Cytokine genetic variations and fatigue among patients with breast cancer. Journal of Clinical Oncology. doi:10. 1200/JCO.2012.46.2143.
14. Brezden, C. B., Phillips, K. A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. [Research Support, Non-U.S. Gov't]. Journal of Clinical Oncology, 18(14), 2695-2701.
15. Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. [Clinical Trial Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. Journal of Clinical and Experimental Neuropsychology, 26(7), 955-969. doi:10.1080/13803390490510905.
16. Chelune, G., Heaton, R., & Lehman, R. (1986). Neuropsychological and personality correlates of patients' complaints of disability. R.E.T. Gerald Goldstein. Advances in Clinical Neuropsychology, 3, 95-126.
17. Collado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S.W., & Irwin, M. R. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Clinical Cancer Research, 12(9), 2759-2766. doi:10.1158/1078-0432.CCR-05-2398.
18. Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., & Verma, S. (2009). Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. [Research Support, Non-U.S. Gov't]. Psycho-Oncology, 18(2), 134-143. doi:10.1002/pon.1379.
19. Correa, D. D., & Ahles, T. A. (2008). Neurocognitive changes in cancer survivors. [Review]. Cancer Journal, 14(6), 396-400. doi:10. 1097/PPO.0b013e31818d8769.
20. Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Van den Stock, J., et al. (2011). Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. [Research Support, Non-U.S. Gov't]. Human Brain Mapping, 32(3), 480-493. doi:10.1002/ hbm.21033.
21. Deprez, S., Amant, F., Smeets, A., Peeters, R., Leemans, A., Van Hecke, W., et al. (2012). Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. [Research Support, Non-U.S. Gov't]. Journal of Clinical Oncology, 30(3), 274-281. doi:10. 1200/JCO.2011.36.8571.
22. Dietrich, J., Monje, M., Wefel, J., & Meyers, C. (2008). Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. [Research Support, Non-U.S. Gov't Review]. The Oncologist, 13(12), 1285-1295. doi:10.1634/ theoncologist.2008-0130.
23. Eisenberger, N. I., Inagaki, T. K., Rameson, L. T., Mashal, N. M., & Irwin, M. R. (2009). An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. NeuroImage, 47(3), 881-890. doi:10.1016/j.neuroimage.2009.04.040.
24. Ferguson, R. J., McDonald, B. C., Saykin, A. J., & Ahles, T. A. (2007). Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. [Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Twin Study]. Journal of Clinical Oncology, 25(25), 3866-3870. doi:10.1200/JCO.2007.10.8639.
25. Friston, K., Ashburner, J., Kiebel, S., Nichols, T., & Penny, W. (2007). Statistical parametric mapping: The analysis of functional brain images. Burlington: Academic.
26. Fritz-French, C., & Tyor, W. (2012). Interferon-alpha (IFNalpha) neurotoxicity. [Review]. Cytokine & Growth Factor Reviews, 23(1-2), 7-14. doi:10.1016/j.cytogfr.2012.01.001.
27. Ganz, P. A., Bower, J. E., Kwan, L., Castellon, S. A., Silverman, D. H., Geist, C., et al. (2012). Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain, Behavior, and Immunity. doi:10.1016/j.bbi.2012.07.015.
28. Ganz, P., Kwan, L., Castellon, S. A., Oppenheim, A., Bower, J. E., Silverman, D., et al. (2013). Cognitive complaints after breast cancer treatments: Is there a relationship to neuropsychological test performance? Journal of the National Cancer Institute.
29. Hannestad, J., Subramanyam, K., Dellagioia, N., Planeta-Wilson, B., Weinzimmer, D., Pittman, B., et al. (2012). Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. Journal of Nuclear Medicine, 53(4), 601-607. doi:10.2967/jnumed.111.097014.
30. Jansen, C. E., Cooper, B. A., Dodd, M. J., & Miaskowski, C. A. (2011). A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Supportive Care in Cancer, 19(10), 1647-1656. doi:10.1007/s00520-010-0997-4.
31. Kesler, S., Janelsins, M., Koovakkattu, D., Palesh, O., Mustian, K., Morrow, G., et al. (2012). Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain, Behavior, and Immunity. doi:10.1016/j.bbi.2012.05.017.
32. Kuo, H. K., Yen, C. J., Chang, C. H., Kuo, C. K., Chen, J. H., & Sorond, F. (2005). Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. [Meta-Analysis Review]. Lancet Neurology, 4(6), 371-380. doi:10.1016/S1474-4422(05)70099-5.
33. Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. [Research Support, Non-U.S. Gov't Review]. Neuroimmunomodulation, 11(5), 279-292. doi:10.1159/000079408.
34. Marsland, A. L., Petersen, K. L., Sathanoori, R., Muldoon, M. F., Neumann, S. A., Ryan, C., et al. (2006). Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. [Research Support, N.I.H., Extramural]. Psychosomatic Medicine, 68(6), 895-903. doi:10.1097/01.psy. 0000238451.22174.92.
35. McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D., & Saykin, A. J. (2010). Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Breast Cancer Research and Treatment, 123(3), 819-828. doi:10. 1007/s10549-010-1088-4.
36. McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D., & Saykin, A. J. (2012). Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Journal of Clinical Oncology, 30(20), 2500-2508. doi:10.1200/ JCO.2011.38.5674.
37. Myers, J. S. (2010). The possible role of cytokines in chemotherapyinduced cognitive deficits. Advances in Experimental Medicine and Biology, 678, 119-123.
38. O'Bryant, S. E., Xiao, G., Barber, R., Reisch, J., Doody, R., Fairchild, T., et al. (2010). A serum protein-based algorithm for the detection of Alzheimer disease. [Research Support, N.I.H., Extramural]. Archives of Neurology, 67(9), 1077-1081. doi:10.1001/archneurol. 2010.215.
39. Orre, I. J., Murison, R., Dahl, A. A., Ueland, T., Aukrust, P., & Fossa, S. D. (2009). Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. [Research Support, Non-U.S. Gov't]. Brain, Behavior, and Immunity, 23(6), 868-874. doi:10. 1016/j.bbi.2009.04.003.
40. Pusztai, L., Mendoza, T. R., Reuben, J. M., Martinez, M. M., Willey, J. S., Lara, J., et al. (2004). Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. [Clinical Trial Comparative Study Controlled Clinical Trial Research Support, Non-U.S. Gov't]. Cytokine, 25(3), 94-102.
41. Rourke, S. B., Halman, M. H., & Bassel, C. (1999). Neuropsychiatric correlates of memory-metamemory dissociations in HIV-infection. [Comparative Study Research Support, Non-U.S. Gov't]. Journal of Clinical and Experimental Neuropsychology, 21(6), 757-768. doi:10.1076/jcen.21.6.757.852.
42. Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. [Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't]. Cancer, 85(3), 640-650.
43. Silverman, D. H., Dy, C. J., Castellon, S. A., Lai, J., Pio, B. S., Abraham, L., et al. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. [Research Support, Non-U.S. Gov't]. Breast Cancer Research and Treatment, 103(3), 303-311. doi:10.1007/s10549-006-9380-z.
44. Silverman, D. H., Geist, C. L., Kenna, H. A., Williams, K., Wroolie, T., Powers, B., et al. (2011). Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. Psychoneuroendocrinology, 36(4), 502-513. doi:10.1016/j.psyneuen.2010.08.002.
45. Talairach, J., & Tournoux, P. (1988). Co-planar stereotaxic atlas of the human brain (3-Dimensional proportional system: An approach to cerebral imaging). New York: Thieme.
46. Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. [Comparative Study Research Support, Non-U.S. Gov't]. Journal of Clinical Oncology, 21(22), 4175-4183. doi:10.1200/ JCO.2003.01.119.
47. Teunissen, C. E., van Boxtel, M. P., Bosma, H., Bosmans, E., Delanghe, J., De Bruijn, C., et al. (2003). Inflammation markers in relation to cognition in a healthy aging population. Journal of Neuroimmunology, 134(1-2), 142-150.
48. Tilvis, R. S., Kahonen-Vare, M. H., Jolkkonen, J., Valvanne, J., Pitkala, K. H., & Strandberg, T. E. (2004). Predictors of cognitive decline and mortality of aged people over a 10-year period. [Research Support, Non-U.S. Gov't]. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 59(3), 268-274.
49. Torres, M. A., Pace, T.W., Liu, T., Felger, J. C., Mister, D., Doho, G. H., et al. (2013). Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer. doi:10.1002/cncr.28003.
50. van Dam, F. S., Schagen, S. B., Muller, M. J., Boogerd, W., vdWall, E., Droogleever Fortuyn, M. E., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. [Clinical Trial Randomized Controlled Trial]. Journal of the National Cancer Institute, 90(3), 210-218.
51. Wang, X. S., Shi, Q., Williams, L. A., Mao, L., Cleeland, C. S., Komaki, R. R., et al. (2010). Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. [Research Support, N.I.H., Extramural]. Brain, Behavior, and Immunity, 24(6), 968-974. doi:10.1016/j.bbi.2010.03.009.
52. Wang, X. S., Williams, L. A., Krishnan, S., Liao, Z., Liu, P., Mao, L., et al. (2012). Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. [Research Support, N.I.H., Extramural]. Brain, Behavior, and Immunity, 26(5), 699-705. doi:10.1016/j.bbi.2011.12.007.
53. Wefel, J. S., & Schagen, S. B. (2012). Chemotherapy-related cognitive dysfunction. [Review]. Current Neurology and Neuroscience Reports, 12(3), 267-275. doi:10.1007/s11910-012-0264-9.
54. Wefel, J. S., Kayl, A. E., & Meyers, C. A. (2004). Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. [Review]. British Journal of Cancer, 90(9), 1691-1696. doi:10.1038/sj. bjc.6601772.
55. Wefel, J. S., Witgert, M. E., & Meyers, C. A. (2008). Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. [Review]. Neuropsychology Review, 18(2), 121-131. doi:10.1007/s11065-008-9058-x.
56. Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010). Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. [Clinical Trial, Phase III Randomized Controlled Trial]. Cancer, 116(14), 3348-3356. doi:10.1002/cncr.25098.
57. WHO (2012). Cancer fact sheet No. 297. http://www.who.int/mediacentre/ factsheets/fs297/en/.